Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GSK NASDAQ:INVA NYSE:NBR NASDAQ:WEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$51.57+0.6%$53.44$35.45▼$61.69$104.54B0.363.33 million shs4.05 million shsINVAInnoviva$22.52+1.6%$22.88$16.52▼$25.15$1.66B0.35885,756 shs845,393 shsNBRNabors Industries$95.83-5.2%$92.89$27.18▼$112.90$1.42B0.96263,283 shs347,038 shsWENWendy's$6.71-0.6%$7.18$6.37▼$12.51$1.28B0.3813.04 million shs10.34 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK0.00%+1.97%+2.14%-5.47%+26.29%INVAInnoviva0.00%+5.14%-1.23%+2.22%+7.85%NBRNabors Industries0.00%+3.11%-0.48%+21.88%+232.04%WENWendy's0.00%-12.86%-3.45%-9.57%-43.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$51.57+0.6%$53.44$35.45▼$61.69$104.54B0.363.33 million shs4.05 million shsINVAInnoviva$22.52+1.6%$22.88$16.52▼$25.15$1.66B0.35885,756 shs845,393 shsNBRNabors Industries$95.83-5.2%$92.89$27.18▼$112.90$1.42B0.96263,283 shs347,038 shsWENWendy's$6.71-0.6%$7.18$6.37▼$12.51$1.28B0.3813.04 million shs10.34 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK0.00%+1.97%+2.14%-5.47%+26.29%INVAInnoviva0.00%+5.14%-1.23%+2.22%+7.85%NBRNabors Industries0.00%+3.11%-0.48%+21.88%+232.04%WENWendy's0.00%-12.86%-3.45%-9.57%-43.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSKGSK 1.89Reduce$53.002.78% UpsideINVAInnoviva 2.57Moderate Buy$36.2060.75% UpsideNBRNabors Industries 2.29Hold$103.437.93% UpsideWENWendy's 1.96Reduce$8.5627.52% UpsideCurrent Analyst Ratings BreakdownLatest INVA, WEN, NBR, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026INVAInnoviva HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.005/26/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.005/13/2026WENWendy's ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$12.005/12/2026WENWendy's TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$6.005/11/2026WENWendy's BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Perform$9.00 ➝ $8.005/11/2026WENWendy's CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$7.25 ➝ $7.755/11/2026WENWendy's JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight$7.00 ➝ $6.005/7/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $42.005/7/2026NBRNabors Industries BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$65.00 ➝ $99.005/4/2026NBRNabors Industries Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/1/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B)(Data available from 6/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSKGSK$43.07B2.43$6.01 per share8.58$10.32 per share5.00INVAInnoviva$411.33M4.04$5.03 per share4.48$15.71 per share1.43NBRNabors Industries$3.21B0.44$35.62 per share2.69$65.60 per share1.46WENWendy's$2.18B0.59$1.80 per share3.73$0.62 per share10.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSKGSK$7.54B$3.8513.4010.072.6417.82%44.28%11.49%7/28/2026 (Estimated)INVAInnoviva$271.17M$6.013.759.27N/A119.89%33.33%22.67%8/5/2026 (Estimated)NBRNabors Industries$286.62M$12.777.5073.15N/A7.32%-8.66%-1.59%7/28/2026 (Estimated)WENWendy's$165.07M$0.788.6010.650.496.77%136.46%3.14%8/14/2026 (Estimated)Latest INVA, WEN, NBR, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026WENWendy's$0.10$0.12+$0.02$0.12$518.03 million$432.30 million5/6/2026Q1 2026INVAInnoviva$0.43$0.44+$0.01$2.22$101.57 million$97.99 million4/28/2026Q1 2026NBRNabors Industries-$2.4907-$1.54+$0.9507-$1.54$769.33 million$783.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGSKGSK$1.813.51%-7.86%47.01%N/AINVAInnovivaN/AN/AN/AN/AN/ANBRNabors IndustriesN/AN/A-100.00%N/AN/AWENWendy's$0.568.35%+18.23%71.79%N/ALatest INVA, WEN, NBR, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GSKGSKquarterly$0.443.71%5/15/20265/15/20267/9/20265/8/2026WENWendy'squarterly$0.147.13%6/1/20266/1/20266/15/20261/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSKGSK0.800.790.52INVAInnoviva0.1921.1320.07NBRNabors Industries2.221.971.82WENWendy's29.251.831.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSKGSK15.74%INVAInnoviva99.12%NBRNabors Industries81.92%WENWendy's85.96%Insider OwnershipCompanyInsider OwnershipGSKGSK10.00%INVAInnoviva2.01%NBRNabors Industries7.29%WENWendy's17.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSKGSK66,8412.03 billion1.83 billionOptionableINVAInnoviva10073.81 million72.33 millionOptionableNBRNabors Industries13,90014.80 million13.72 millionOptionableWENWendy's14,900190.48 million157.91 millionOptionableINVA, WEN, NBR, and GSK HeadlinesRecent News About These CompaniesWhy Wendy’s new rule-breaking branding might be secretly geniusJune 5 at 12:13 PM | msn.comWendy's teases banana swirl Frosty inspired by Minions movieJune 5 at 12:13 PM | msn.comLocal Wendy’s franchisee Dennis Sumler receives prestigious national “Living Dave’s Legacy Award”June 4 at 3:31 PM | wbbjtv.comWYou have to try this copycat Wendy's strawberry summer salad recipeJune 4 at 3:31 PM | msn.comWendy's wants to give you a free Canon camera. Here's how to get oneJune 3, 2026 | palmbeachpost.comPWendy's (WEN) Q1 2026 Earnings Call TranscriptJune 1, 2026 | finance.yahoo.comUncover the Real Story Behind the Wendy's Logo and Its Unique EvolutionJune 1, 2026 | yahoo.comThe Real Story Behind Wendys Famous Logo Revealed Did You Ever Notice This Hidden Detail?June 1, 2026 | msn.comHow McDonald's beat Wendy's and Burger King on valueMay 28, 2026 | msn.comWendy's Canada Steps Up to the Plate as the Official Hamburger of the Blue Jays™May 28, 2026 | finance.yahoo.comWendy’s US president: The CEO burger battles exposed a truth every brand leader needs to hearMay 28, 2026 | msn.comWendy’s celebrates redheads with look-alike contest. See the freckled competition.May 28, 2026 | usatoday.comWendy's look-alike contest draws fans with red wigs, pigtailsMay 27, 2026 | usatoday.comYou can score a free Wendy's soccer jersey. How to get oneMay 27, 2026 | usatoday.comWendy’s is holding a look-alike contest—with a grand prize of free burgers for a year—to celebrate World Redhead DayMay 26, 2026 | yahoo.comWendy’s look-alike contest offers free burgers for a yearMay 26, 2026 | yahoo.comWendy's is holding a look-alike contest—with a grand prize of free burgers for a year—to celebrate World Redhead DayMay 26, 2026 | fastcompany.comFWhy Wendy's is struggling in 2026May 25, 2026 | msn.comMcDonald's and Wendy's both use all white meat chicken — so why do their nuggets taste so different?May 25, 2026 | msn.comHere's How To Get Fresh Fries At Wendy'sMay 25, 2026 | yahoo.comZacks Research Has Bearish Outlook for Wendy's Q2 EarningsMay 25, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Why Trump’s Amazon Stock Sale May Not Matter at AllBy Sam Quirke | May 19, 2026A Real Biggie Deal: Wendy's Serves Up a Juicy Buyout ArbitrageBy Jeffrey Neal Johnson | May 13, 2026INVA, WEN, NBR, and GSK Company DescriptionsGSK NYSE:GSK$51.57 +0.30 (+0.58%) Closing price 06/5/2026 03:59 PM EasternExtended Trading$51.44 -0.13 (-0.24%) As of 06/5/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Innoviva NASDAQ:INVA$22.52 +0.36 (+1.62%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$22.52 +0.00 (+0.02%) As of 06/5/2026 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Nabors Industries NYSE:NBR$95.83 -5.26 (-5.21%) Closing price 06/5/2026 03:59 PM EasternExtended Trading$95.90 +0.08 (+0.08%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nabors Industries Ltd. provides drilling and drilling-related services for land-based and offshore oil and natural gas wells in the United States and internationally. The company operates through four segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. It provides tubular running services, including casing and tubing running, and torque monitoring; managed pressure drilling services; and drilling-bit steering systems and rig instrumentation software. The company also offers drilling systems comprising ROCKit, a directional steering control system; SmartNAV, a collaborative guidance and advisory platform; SmartSLIDE, a directional steering control system; and RigCLOUD, a digital infrastructure to integrate applications to deliver real-time insight into operations across the rig fleet. In addition, it operates a fleet of land-based drilling rigs and marketed platforms rigs; manufactures and sells top drives, catwalks, wrenches, drawworks, and other drilling related equipment, such as robotic systems and downhole tools; and provides aftermarket sales and services for the installed base of its equipment. Nabors Industries Ltd. was founded in 1952 and is based in Hamilton, Bermuda.Wendy's NASDAQ:WEN$6.71 -0.04 (-0.59%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$6.74 +0.03 (+0.39%) As of 06/5/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Petco Faces Tough Competition, But Momentum Is Building IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
